title: Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia.
authors.forename: F A
authors.initials: FA
authors.lastname: Fierro
authors.forename: S
authors.initials: S
authors.lastname: Brenner
authors.forename: U
authors.initials: U
authors.lastname: Oelschlaegel
authors.forename: A
authors.initials: A
authors.lastname: Jacobi
authors.forename: H
authors.initials: H
authors.lastname: Knoth
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
authors.forename: T
authors.initials: T
authors.lastname: Illmer
authors.forename: M
authors.initials: M
authors.lastname: Bornhäuser
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001596:Benzylamines; D002465:Cell Movement / Q000187:drug effects; D054377:Chemokine CXCL12 / Q000037:antagonists & inhibitors*; D000080027:Cyclams; D006571:Heterocyclic Compounds / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*; D012008:Recurrence
chemical_list: D000970:Antineoplastic Agents; D001596:Benzylamines; C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D000080027:Cyclams; D006571:Heterocyclic Compounds; D019718:Receptors, CXCR4; C088327:plerixafor